Creating DNAm Algorithms Using the Illumina Methylation Screening Array (MSA)
Most established DNA methylation (DNAm) biomarkers were developed on legacy Illumina EPIC arrays. The Infinium Methylation Screening Array (MSA) offers a lower-cost, higher-throughput alternative with reduced probe content, but EPIC-trained algorithms cannot be assumed to transfer directly. Here we present a reproducibility-based framework for developing and transferring DNAm algorithms on the MSA. Using paired biological replicates profiled on EPICv1 and MSA (1,764 EPICv1-MSA sample pairs, plus within-array MSA replicates on the same and different beadchips), we quantified probe-level agreement using mean absolute error (MAE) and intraclass correlation coefficients (ICC). Of 140,150 CpG sites shared between EPICv1 and MSA, 40,786 (29.1%) met both stability criteria (MAE < 0.05 and ICC(2,k) > 0.6). This stable feature space supported two modelling streams. First, we trained 134 epigenetic biomarker proxies (EBPs) natively on MSA, with and without kernel principal component analysis (kPCA) for sample-level harmonisation. All 134 reached same-beadchip ICC(2,1) >= 0.80 (median 0.97) and 96.3% reached different-beadchip ICC(2,1) >= 0.60 (median 0.81), with a median Spearman correlation of 0.48 against observed values. Among the 72 kPCA-selected models with a comparable stable-probe baseline, 70 (97%) showed higher cross-beadchip ICC (median improvement +0.18). Second, we transferred three established clocks using model-specific strategies: OMICmAge and SystemsAge were retrained to estimate their EPICv1-derived values (held-out test-set rho = 0.944 and 0.912-0.949), whereas DunedinPACE required stable-probe normalisation and robust linear calibration, which raised cross-array ICC(2,1) from 0.784-0.810 to 0.891-0.925 and reduced MAE from 0.085-0.089 to 0.041-0.050 across three sample sets. Reduced probe content does not preclude reproducible DNAm biomarker measurement, and transfer strategy must be matched to model architecture.